Results 11 to 20 of about 23,148 (170)

Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial

National Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: On 18th June 2013, India banned pioglitazone, a peroxisome proliferation activator gamma agonist, and a popular anti-diabetic drug used in the treatment of type 2 diabetes mellitus (T2DM), but on 21st August 2013, ban was revoked after stiff ...
Allen Joe Rodrigues, Laxminarayana Kamath, Shreya Chokshi, Raveendra K R   +3 more
doaj   +1 more source

Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice

Toxicology Reports, 2016
Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. In
Yuzuru Iizuka, Hyounju Kim, Maki Nakasatomi, Takuya Izawa, Satoshi Hirako, Akiyo Matsumoto   +5 more
doaj   +1 more source

A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone

Perspectives in Clinical Research, 2021
Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer.
Prabhat Agrawal, Apoorva Jain, Ashish Gautam, Ashwini Kumar Nigam, Nikhil Pursnani, Maaz Farooqui   +5 more
doaj   +1 more source

Probiotics ameliorate pioglitazone-associated bone loss in diabetic rats

Diabetology & Metabolic Syndrome, 2020
Background Pioglitazone, as a PPAR gamma agonist, is used for the management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPAR gamma activity using pioglitazone might be linked with bone mass reduction and
Ahmad Gholami, Mohammad Hossein Dabbaghmanesh, Younes Ghasemi, Pedram Talezadeh, Farhad Koohpeyma, Nima Montazeri-Najafabady   +5 more
doaj   +1 more source

Pioglitazone and metformin

Drugs of Today, 2007
Pioglitazone and metformin have both proven safe and efficacious in the treatment of type 2 diabetes. Their combination into a single tablet seems logical. This article reviews the data that are available for this combination. Because the tablets are not currently widely available, the review examines some aspects of the effects of both agents ...
Hill, N, Matthews, DR
openaire   +3 more sources

Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome

Journal of Pharmacological Sciences, 2019
Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS).
Tsukasa Nozu, Saori Miyagishi, Rintaro Nozu, Kaoru Takakusaki, Toshikatsu Okumura   +4 more
doaj   +1 more source

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study

Cardiovascular Diabetology, 2020
Background Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare.
Yi-Chih Hung, Lu-Ting Chiu, Hung-Yu Huang, Da-Tian Bau   +3 more
doaj   +1 more source

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.

PLoS ONE, 2018
BackgroundChoices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects.
Bancha Satirapoj, Khanin Watanakijthavonkul, Ouppatham Supasyndh   +2 more
doaj   +1 more source

A systematic review and meta-analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D). [PDF]

Diabet Med
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Kelly M, Saluja S, Ellis HL, Jamil S, Whyte MB, Heald A.   +5 more
europepmc   +2 more sources

Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats

Frontiers in Pharmacology, 2017
Pioglitazone is a type of peroxisome proliferator-activated receptor γ (PPARγ) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment.
Li Sun, Quan Yuan, Tianhua Xu, Li Yao, Jiangmin Feng, Jianfei Ma, Lining Wang, Changlong Lu, Danan Wang   +8 more
doaj   +1 more source